Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Saved in:
| Title: | Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. |
|---|---|
| Authors: | Chanan-Khan, Asher1 Chanan-Khan.Asher@mayo.edu, Cramer, Paula2, Demirkan, Fatih3, Fraser, Graeme4, Silva, Rodrigo Santucci5, Grosicki, Sebastian6, Pristupa, Aleksander7, Janssens, Ann8, Mayer, Jiri9, Bartlett, Nancy L10, Dilhuydy, Marie-Sarah11, Pylypenko, Halyna12, Loscertales, Javier13, Avigdor, Abraham14, Rule, Simon15, Villa, Diego16, Samoilova, Olga17, Panagiotidis, Panagiots18, Goy, Andre19, Mato, Anthony19,20 |
| Source: | Lancet Oncology. Feb2016, Vol. 17 Issue 2, p200-211. 12p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
